Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12419357 | 0.93 | LPL (0.32) | LPLLIPG | |
| SCHEMBL1773236 | 0.76 | MEN1 (0.41) | SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL28286625 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2 | |
| SCHEMBL25585 | 0.75 | ALDH1A1 (0.41) | SMN1; SMN2 | |
| SCHEMBL2882191 | 0.74 | CA2 (0.43) | SMN1; SMN2 | |
| SCHEMBL27595482 | 0.71 | ALDH1A1 (0.46) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL448797 | 0.71 | ALDH1A1 (0.41) | SMN1; SMN2 | |
| SCHEMBL29911017 | 0.71 | LPL (0.40) | SMN1; SMN2LPLLIPG | |
| SCHEMBL21154704 | 0.71 | ALDH1A1 (0.40) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL3950950 | 0.69 | ALDH1A1 (0.40) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | SMN1; SMN2 3053/4885L3MBTL1 4079/4885LPL 116/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | SMN1; SMN2 3053/4885L3MBTL1 4079/4885LPL 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.